New drug cocktail targets superbug pneumonia in hospitals

NCT ID NCT07326540

Recruiting now Disease control Sponsor: BioVersys SAS Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 16 times

Summary

This study tests a new combination of antibiotics (BV100 plus low-dose polymyxin B) against a standard treatment for a serious lung infection caught in the hospital. The infection is caused by bacteria that are resistant to many current drugs. About 248 adults will take part to see if the new combo reduces deaths and cures the infection better than the standard approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOSPITAL ACQUIRED BACTERIAL PNEUMONIA (HABP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University Hospital
RECRUITING

Tbilisi, Georgia

Conditions

Explore the condition pages connected to this study.

ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX COLISTIN RESISTANRT ABC HOSPITAL ACQUIRED BACTERIAL PNEUMONIA (HABP) VENTILATOR ASSOCIATED BACTERIAL PNEUMONIA (VABP)